Ademi LLP is investigating possible securities fraud claims against Cellebrite (NASDAQ: CLBT). The investigation results from inaccurate statements Cellebrite may have made regarding its financial statements, business operations and prospects.
The investigation focuses on recent disclosures regarding risks and Cellebrite’s ability to execute with respect U.S. federal and European government opportunities, which were encountering additional administrative and procurement requirements related to Cellebrite’s foreign-entity status.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Join this Action